Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation

by Tomer Meirson, Nethanel Asher, David Bomze, Gal Markel
Published 2020-06-01

Normal Modes Expose Active Sites in Enzymes.

by Yitav Glantz-Gashai, Tomer Meirson, Abraham O Samson
Published 2016-12-01

Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience

by Nethanel Asher, Noa Israeli-Weller, Ronnie Shapira-Frommer, Guy Ben-Betzalel, Jacob Schachter, Tomer Meirson, Gal Markel
Published 2021-06-01

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma

by Nethanel Asher, Guy Ben-Betzalel, Shaked Lev-Ari, Ronnie Shapira-Frommer, Yael Steinberg-Silman, Neta Gochman, Jacob Schachter, Tomer Meirson, Gal Markel
Published 2020-08-01

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy

by Ronnie Shapira-Frommer, Elad Jacoby, Orit Itzhaki, Abraham Nissani, Gal Markel, Jacob Schachter, Shaked Lev-Ari, Tomer Meirson, Nethanel Asher, Guy Ben-Betzalel, Michal J. Besser
Published 2021-05-01

Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and Activation

by Liat Ninio, Abraham Nissani, Tomer Meirson, Tom Domovitz, Alessandro Genna, Shams Twafra, Kolluru D. Srikanth, Roba Dabour, Erez Avraham, Ateret Davidovich, Hava Gil-Henn, Meital Gal-Tanamy
Published 2019-11-01

Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.

by Shira Perez, Antony Kaspi, Tom Domovitz, Ateret Davidovich, Anat Lavi-Itzkovitz, Tomer Meirson, Jacinta Alison Holmes, Chia-Yen Dai, Chung-Feng Huang, Raymond T Chung, Assy Nimer, Assam El-Osta, Gur Yaari, Salomon M Stemmer, Ming-Lung Yu, Izhak Haviv, Meital Gal-Tanamy
Published 2019-06-01